Pluristem's PLX-PAD Plans Boosted by $36M Offering
By Jennifer Boggs
Friday, January 28, 2011
A week after disclosing plans for an upcoming Phase II/III trial of placenta-derived cell therapy PLX-PAD in critical limb ischemia (CLI), Pluristem Therapeutics Inc. is securing some much-needed funding in a public offering.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.